AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
6,159.00GBp
22 Feb 2019
6,159.00GBp
22 Feb 2019
Change (% chg)
63.00 (+1.03%)
63.00 (+1.03%)
Prev Close
6,096.00
6,096.00
Open
6,100.00
6,100.00
Day's High
6,197.00
6,197.00
Day's Low
6,081.00
6,081.00
Volume
1,724,090
1,724,090
Avg. Vol
2,079,986
2,079,986
52-wk High
6,432.48
6,432.48
52-wk Low
4,710.50
4,710.50
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Dec '18 | 6,417.00 | 0.816 |
| Sep '18 | 5,340.00 | 0.340 | |
| Jun '18 | 5,155.00 | 0.276 | |
| Mar '18 | 5,178.00 | 0.268 | |
| FY 2017 | Dec '17 | 5,777.00 | 1.048 |
| Sep '17 | 6,232.00 | 0.541 | |
| Jun '17 | 5,051.00 | 0.376 | |
| Mar '17 | 5,405.00 | 0.424 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Mar-19 | 6 | 5,443.46 | 5,692.76 | 5,236.00 | 5,531.36 |
| Quarter Ending Jun-19 | 6 | 5,578.02 | 5,657.70 | 5,485.00 | 5,337.68 |
| Year Ending Dec-19 | 26 | 23,492.90 | 24,671.00 | 22,162.00 | 23,847.80 |
| Year Ending Dec-20 | 24 | 25,861.10 | 29,030.00 | 23,698.40 | 25,961.40 |
| Earnings (per share) | |||||
| Quarter Ending Mar-19 | 5 | 0.82 | 0.97 | 0.69 | 1.01 |
| Quarter Ending Jun-19 | 4 | 0.76 | 0.88 | 0.65 | 0.95 |
| Year Ending Dec-19 | 27 | 3.65 | 4.16 | 3.00 | 3.98 |
| Year Ending Dec-20 | 24 | 4.48 | 5.54 | 3.61 | 4.71 |
| LT Growth Rate (%) | 3 | 10.25 | 13.80 | 3.75 | 4.43 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 22.12 | 30.48 | 33.70 | |
| P/E High - Last 5 Yrs. | 72.73 | 44.98 | 49.87 | |
| P/E Low - Last 5 Yrs. | 9.58 | 23.63 | 24.25 | |
| Beta | 1.04 | 0.90 | 0.90 | |
| Price to Sales (TTM) | 3.94 | 4.12 | 6.29 | |
| Price to Book (MRQ) | 6.27 | 5.10 | 5.26 | |
| Price to Tangible Book (MRQ) | -- | 5.85 | 6.77 | |
| Price to Cash Flow (TTM) | 13.70 | 24.01 | 24.98 | |
| % Owned Institutions | -- | 0.90 | 1.69 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.49 | 1.40 | |
| Dividend Yield - 5 Year Avg | 5.55 | 1.51 | 1.42 | |
| Dividend 5 Year Growth Rate | 4.86 | 4.15 | 4.85 | |
| Payout Ratio(TTM) | 62.12 | 43.91 | 41.03 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -9.85 | 4.31 | 12.76 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -9.65 | 4.07 | 5.84 | |
| Sales - 5 Yr. Growth Rate | -7.29 | 10.91 | 11.23 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 15,985.23 | 44.94 | 47.15 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 74.09 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -17.55 | 10.31 | 10.85 | |
| Capital Spending - 5 Yr. Growth Rate | 12.28 | 15.88 | 15.20 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.73 | 2.15 | 2.25 |
| Current Ratio (MRQ) | 0.91 | 2.97 | 3.08 |
| LT Debt to Equity (MRQ) | 122.99 | 8.85 | 11.38 |
| Total Debt to Equity (MRQ) | 144.47 | 12.89 | 16.12 |
| Interest Coverage (TTM) | 4.61 | 33.79 | 29.47 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 82.88 | 53.68 | 53.81 | |
| Gross Margin - 5 Yr. Avg. | 80.69 | 51.67 | 52.18 | |
| EBITD Margin (TTM) | 38.95 | -- | -- | |
| EBITD - 5 Yr. Avg | 31.99 | 17.96 | 12.87 | |
| Operating Margin (TTM) | 24.85 | 14.31 | 6.19 | |
| Operating Margin - 5 Yr. Avg. | 17.97 | 14.24 | 8.31 | |
| Pre-Tax Margin (TTM) | 18.09 | 14.85 | 7.15 | |
| Pre-Tax Margin - 5 Yr. Avg. | 14.67 | 14.68 | 8.61 | |
| Net Profit Margin (TTM) | 17.34 | 11.08 | 3.29 | |
| Net Profit Margin - 5 Yr. Avg. | 12.74 | 11.02 | 4.89 | |
| Effective Tax Rate (TTM) | 4.14 | 23.02 | 22.91 | |
| Effective Tax Rate - 5 Yr. Avg. | 13.16 | 23.16 | 23.38 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 278,767 | 957,633,895 | 842,388,263 | |
| Net Income/Employee (TTM) | 48,342 | 113,563,162 | 99,841,601 | |
| Receivable Turnover (TTM) | 4.36 | 5.71 | 5.71 | |
| Inventory Turnover (TTM) | 1.40 | 2.61 | 3.47 | |
| Asset Turnover (TTM) | 0.34 | 0.97 | 0.93 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 5.82 | 11.52 | 11.06 | |
| Return on Assets - 5 Yr. Avg. | 5.71 | 12.92 | 12.20 | |
| Return on Investment (TTM) | 7.86 | 14.95 | 14.45 | |
| Return on Investment - 5 Yr. Avg. | 7.89 | 16.84 | 15.87 | |
| Return on Equity (TTM) | 28.47 | 16.27 | 15.96 | |
| Return on Equity - 5 Yr. Avg. | 15.71 | 17.77 | 17.00 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -6.90 | -3.76 | -7.29 |
| EPS (TTM) % | 23.76 | 10.68 | -17.55 |
| Dividend % | 26.80 | 8.24 | 4.86 |
Note: Units in Millions of US Dollars
Performance for AstraZeneca PLC
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 7.60 | 5.39 | 99 | 22 |
| 13 Week | 0.47 | -2.14 | 99 | 39 |
| 26 Week | 7.52 | 4.45 | 99 | 33 |
| 52 Week | 2.55 | -5.39 | 99 | 9 |
| YTD | 16.15 | 8.98 | 99 | 26 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 2-HSBC, stronger pound pressure FTSE 100; Greggs outshines mid-caps
- UPDATE 2-FTSE 100 dips as investors book in profits, pound strengthens; Reckitt shines
- FTSE 100 squeezes out gains; ConvaTec drags midcaps
- GLOBAL MARKETS-Fall in U.S. retail sales dampens world stock market rally
- GLOBAL MARKETS-Fall in U.S. retail sales dampens world stock market rally
Institutional Holders
| % Shares Owned: | 56.32% |
| # of Holders: | 591 |
| Total Shares Held: | 713,581,343 |
| 3 Mo. Net Change: | -7,313,624 |
| # New Positions: | 18 |
| # Closed Positions: | 16 |
| # Increased Positions: | 159 |
| # Reduced Positions: | 160 |
| # Net Buyers: | -1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks